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Abstract 26 
 27 
The efficacy of antibiotic treatment of clinical mastitis (CM) is classically evaluated using 28 
bacteriological cure. This provides a concise and objective way of assessing efficacy, but unfortunately 29 
does not reflect the field situation where persistence or recurrence of clinical signs lead to perceived 30 
treatment failure. If clinical signs persist or recur, intramammary (IMM) treatment is often extended or 31 
supplemented with parenteral treatment, in the expectation of a more efficient elimination of clinical 32 
signs or a lower probability of recurrence of clinical signs. The objective of this study was to evaluate 33 
the efficacy against clinical persistence or recurrence of three cefquinome treatment regimes, standard 34 
1.5-day intramammary (SIMM), 5-day extended intramammary (EIMM) and combination of EIMM 35 
plus 5-day extended parenteral (ECOMBO) treatment. The study was conducted on three dairy farms 36 
with a high recurrence rate of environmental mastitis. Efficacy was evaluated using a multi-level model 37 
at the quarter and at the cow level, based on the persistence or recurrence of clinical signs at any time 38 
during a 105-day period following the end of the initial treatment, independent of pathogen. The most 39 
prevalent pathogens were E. coli (16.9%) and S. uberis (11.97%). EIMM and ECOMBO significantly 40 
decreased the persistence or recurrence of CM by 8 % and 6 % at the quarter level and by 9 % and 8 % 41 
at the cow level, respectively. ECOMBO may not reduce the persistence or recurrence of CM beyond 42 
EIMM. Whilst extended treatment regimens offered an improved outcome in this study, the producer 43 
and practitioner need to carefully consider such regimens from the perspective of prudent antibiotic use.  44 
 45 
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 47 
Introduction 48 
Environmental pathogens, particularly Streptococcus uberis and Escherichia coli, can be a cause 49 
of persistent intramammary infection (Van Eennenaam et al., 1995, Döpfer et al., 1999, Bradley and 50 
Green, 2001). On some farms, with a low bulk milk somatic cell count (BMSCC) and high incidence of 51 
clinical mastitis (CM), a significant proportion of CM may occur in a limited number of animals as a 52 
result of a high level of recurrence (Houben et al., 1993, Lam et al., 1996, Zadoks et al., 2001). 53 
Recurrent CM cases have been described as being as severe as index cases, with comparable impact on 54 
milk yield and probability of death (Bar et al., 2007). Moreover, cows with recurrent CM are at a higher 55 
risk for culling (Bar et al., 2008).  56 
 57 
Recurrent CM is usually defined by initial disappearance and subsequent re-occurrence of 58 
clinical signs after a preset number of days. Using this definition, recurrent CM can be due to a 59 
recrudescence of a persistent IMM infection due to failure to cure (Pinzón-Sánchez et al., 2011), or as a 60 
result of re-infection of the quarter after successful cure. However, differentiating between persistence 61 
of infection and re-infection is not possible in the field. Generally, in practice, the disappearance of 62 
clinical signs is considered as cure, whereas persistence or recurrence of clinical signs is considered as 63 
treatment failure. This treatment failure is what is evaluated in this study. 64 
 65 
One of the consequences of successful elimination of the causative bacteria is a shortened  66 
timeframe during which infection can spread to other cows in the herd, via the milking machine, the 67 
milker or the environment. Potentially, improving bacteriological cure rates decreases the infection 68 
pressure on healthy cows and, thus, prevents new CM cases. At the same time bacteriological cure also 69 
prevents the recrudescence of persistent infections (Van Eenennaam et al., 1995). These indirect effects 70 
of cure may play a role in decreasing the overall incidence of CM. 71 
 72 
A number of approaches to improve bacteriological cure of CM have been evaluated, such as 73 
extending treatment duration (Sol et al., 2000, Oliver et al., 2004, Milne et al., 2005) and additional 74 
parenteral therapy (Shpighel et al., 1997, Erskine et al., 2002, Wenz et al., 2005). However, such studies 75 
have not evaluated the long-term outcome of treatment, nor do they necessarily accurately reflect the 76 
field situation where CM treatment outcomes are assessed by the elimination of clinical signs, such as 77 
abnormal milk, swelling or redness of the udder. In the field, if clinical signs persist or recur, 78 
intramammary (IMM) treatment is often extended or reinstated with parenteral treatment in the 79 
expectation of a more effective elimination of clinical signs, leading to the use of additional antibiotic on 80 
farm. However, there are few reports on the effects of extended treatment, with or without parenteral 81 
treatment, on CM persistence or recurrence. 82 
 83 
Clinical mastitis can be treated with different types of antibiotics. Cefquinome is a broad-84 
spectrum β-lactam antibiotic for the treatment of CM, via the IMM and parenteral routes and is licensed 85 
as a combination therapy for E. coli mastitis in the UK. Concurrent use of IMM and parenteral 86 
cefquinome in CM has been evaluated (Shpigel et al., 1997, Ehinger et al, 2006). In herds in which 87 
environmental mastitis predominates, the etiology is necessarily diverse thereby demanding a broad-88 
spectrum antibiotic for first treatment of CM in the absence of previous identification of the causative 89 
pathogen. 90 
The aim of this study was to evaluate the effect of different cefquinome treatment regimes in a 91 
field based context on the likelihood of clinical persistence or recurrence of CM in dairy herds with high 92 
recurrence rates of environmental mastitis. 93 
 94 
Material and Methods 95 
 96 
Farms 97 
 98 
Three commercial dairy farms in Somerset, UK, were selected on the basis of access to electronic 99 
records, a history of a high rate of recurrence of CM and a predominance of environmental mastitis (Table 100 
1). CM cases were sampled from August 2009 until November 2010. Monthly milk production, individual 101 
cow somatic cell count (SCC) and all CM cases had been recorded for at least 12 months prior to the start of 102 
the study. Milking protocols were comparable between farms, post milking teat disinfection, pre-dipping or 103 
pre-wiping and inspection for CM was practiced on all farms in all cows throughout lactation. Milking 104 
procedures and equipment did not change during the study period. All three farms used blanket antibiotic 105 
dry cow treatment. 106 
 107 
Animals 108 
 109 
Lactating Holstein Friesian dairy cows with CM in one or more quarters were enrolled. Animal 110 
parity, yield, historic SCC, CM history, treatment history and relevant clinical data were recorded 111 
contemporaneously onto data capture forms or retrieved from on-farm software. 112 
 113 
Inclusion and exclusion criteria 114 
 115 
Cows were eligible for the study if they were in good general health and had four functional 116 
quarters free from clinically significant udder, teat and teat orifice lesions. Cows were followed for 105 117 
days after treatment and when cows were dried off or removed from the herd earlier, right censoring was 118 
used. Data from animals that were dried off or removed from the herd due to death or culling were 119 
analysed until the day of dry off or removal.  120 
 121 
Treatment allocation 122 
 123 
Cows were randomly allocated to a treatment group, by the herdspersons based on line numbers. 124 
Line numbers were allocated randomly on farm at the moment animals joined the herd. Cows that 125 
developed CM were sampled aseptically before treatment, according to their pre-assigned treatment 126 
group. When clinical signs did not resolve (‘treatment failure’) during the 105 day period after the last 127 
treatment of an animal’s first enrolled clinical case, or if clinical signs disappeared and recurred at any 128 
time point during that period, the cows were treated again with the same treatment regime on all 129 
subsequent occasions.  130 
 131 
Treatment 132 
 133 
All treatments were administered by farm personnel and three different regimes were evaluated;  134 
1) 1.5-day IMM treatment with cefquinome 75 mg  (Cobactan LC, MSD Animal Health), twice on the 135 
first day, at two consecutive milkings and once, at the morning milking on the following day (SIMM),  136 
2) 5-day IMM treatment with cefquinome 75 mg, six times, twice on the first day, at two consecutive 137 
milkings, 4 times once a day, at the morning milking (EIMM),  138 
3) 5-day combination treatment with cefquinome 75 mg IMM, six times, twice on the first day at two 139 
consecutive milkings and once, at the morning milking on the following 4 days, plus cefquinome 140 
sulphate suspension (1 mg/kg, Cobactan 2.5%, MSD Animal Health) by intramuscular injection five 141 
times at 24-hour intervals (ECOMBO). 142 
 143 
Post admission withdrawal 144 
 145 
Animals were withdrawn post admission due to missing data, injury or disability or 146 
abnormalities, or concomitant disease or disease other than CM requiring antibiotic or anti-inflammatory 147 
treatment.  148 
 149 
Detection of CM, persistence of clinical signs and milk sampling 150 
 151 
CM was defined as a quarter with any visible change of milk aspect and was identified by farm 152 
personnel, who had been trained and assessed in the detection, classification and sampling of CM. 153 
Individual cases were assessed for persistence or recurrence of clinical signs at every milking (twice 154 
daily on two units and thrice daily on one unit).  The severity of CM was classified using a three-grade 155 
scale:  Grade 1, mild (only clots in the milk); Grade 2, moderate (milk aspect changes in colour and / or 156 
consistency and / or presence of clots, heat, pain and/or swelling of the udder); and Grade 3, severe 157 
(milk aspect changes in colour and / or consistency and / or presence of clots, fever, depression, 158 
anorexia, very swollen udder).  159 
Any concurrent treatments were also recorded. Prior to treatment farm personnel collected milk samples 160 
from affected quarters. Milk samples were frozen (-20 °C) and collected for submission to the laboratory 161 
on a weekly basis. 162 
 163 
Laboratory Methods 164 
 165 
Microbiological investigation and SCC were carried out using the standard milk sample 166 
examination techniques, according to the standard recommended by the International Dairy Federation 167 
(Bulletin No 132, 1981), International Standard 13366-1:1997 (E) and 13366-2:1997 (G). More 168 
specifically, 3 plates were used, 10 L of secretion was inoculated onto sheep blood agar and Edward’s 169 
agar; 100 L of secretion was inoculated onto MacConkey agar to enhance the detection of 170 
Enterobacteriaceae before incubation at 37 oC. All plates were read at 24, 48, and 72 h.  Organisms 171 
were identified and quantified using standard laboratory techniques (NMC, 1999; Quinn et al., 1994). 172 
Escherichia coli was identified by colony morphology, oxidase, and indole tests; other 173 
Enterobacteriaceae were identified using a microtube identification system (RapiD 20 E, bioMérieux, 174 
Basingstoke, UK). 175 
 176 
Efficacy of treatment 177 
 178 
Treatment was considered effective if clinical signs had resolved after the last treatment and did 179 
not recur in the 105 day period after treatment, independent of the bacteria involved. To allow 180 
assessment of the potential benefits of systemic treatment on concurrently infected (but not clinically 181 
affected) quarters, efficacy was assessed at the quarter and cow level. At the quarter level, lack of 182 
efficacy was based on clinical persistence or clinical recurrence of CM in the same quarter. At the cow 183 
level, lack of efficacy was based on clinical persistence or clinical recurrence of CM in the same cow, 184 
irrespective of the quarter involved.  185 
 186 
Data handling and Statistical analysis 187 
 188 
In this randomized, positive controlled, unmasked, three treatment group study, the null 189 
hypothesis was that there was no difference in time to clinical recurrence of CM between groups. This 190 
hypothesis was analyzed in a multi-level model. The clinically affected quarter was the experimental 191 
unit, with the subsequent analysis taking into account the effect of clustering of cases within quarters, 192 
and quarters within cows. Inevitably in studies such as this some cows were allocated to treatment group 193 
incorrectly. In order to ensure compliance in a large field based study such as this, farmers were allowed 194 
some discretion in individual cow treatment allocation.  Analysis explored the impact of deviations from 195 
the predefined treatment protocols. 196 
 197 
Cow and farm data were transferred to a database (Microsoft Access 2003) and all fields were 198 
checked for unusual or impossible entries. Data fields were coded as categorical or continuous, as 199 
appropriate, and data transformations carried out for continuous data to normalize distribution, when 200 
necessary.  201 
 202 
The outcome variable of interest was the persistence or recurrence of clinical signs of mastitis after 203 
the end of treatment.  Initial analysis consisted of descriptive statistics and graphical assessment. 204 
Conventional Kaplan-Meier survival curves were constructed to provide a visual display of clinical 205 
persistence or recurrence (‘treatment failure’) of CM. To construct this curve, the 105 day post treatment 206 
study period was divided into 7-day blocks. Each case in each block was coded as recurrent or persistent 207 
(CM=1) or not recurrent or persistent (CM=0) at the quarter level. Cows were censored at the end of the 208 
105-day follow-up period, at the end of lactation, or after death or culling. Discrete time survival models 209 
with random effects were specified so that correlations within the data (cases within quarters and quarters 210 
within cows) were accounted for as appropriate in a (frailty) model. The model took the form; 211 
 212 
CMtijk ~ Bernoulli probability (mean = µtijk) 213 
 214 
Logit (µtijk) = α + log ttijk + log ttijk2 + log ttijk3 + log ttijk4 + β1Xijk + β2Xjk + β3Xk + ujk  + vk   215 
        216 
where t is the week of lactation after previous CM, i, j  and k denote the ith CM case in the jth quarter of the 217 
kth cow, πijk the fitted probability of clinical persistence or recurrence of CM after treatment for case i in 218 
quarter j of cow k, α the regression intercept, Xijk the vector of covariates at case level, β1 the coefficients 219 
for covariates Xik, Xjk the vector of quarter level covariates, β2 the coefficients for covariates Xjk, Xk the 220 
vector of cow level covariates, β3 the coefficients for covariates Xk, uj the random effect to reflect residual 221 
variation between quarters and vk the random effect to reflect residual variation between cows (both random 222 
effects assumed to be normally distributed with mean = 0 and variances Ωu and Ωv respectively). 223 
 224 
 The distributions of covariates were assessed and transformations or re-categorization carried out 225 
as deemed appropriate on biological grounds. Model building was carried out using MLwiN with 226 
penalized quasi-likelihood for parameter estimation (Rasbash et al., 2010). To avoid the potential biased 227 
estimates that can arise from quasi-likelihood methods (Browne and Draper, 2006) final models were 228 
selected using Markov chain Monte Carlo (MCMC) for parameter estimation in WinBUGS 229 
(Spiegelhalter et al., 2004) using methods described in detail previously (Green et al., 2004). Covariates 230 
remained in the model when the 95% credibility intervals for the odds ratios did not include 1.00. 231 
Biologically plausible interactions between significant covariates were tested and included when the 232 
95% credibility intervals for the odds ratio of the interaction term did not include 1.00.  233 
 234 
Predictions of the survival time to clinical persistence or recurrence of CM after treatment were 235 
made using posterior predictive assessments (Gelman et al., 1996, Green et al., 2007). This incorporates 236 
the full model posterior predictive distribution, and was used to evaluate model fit and to illustrate the 237 
predicted impact of treatment on time to recurrence of CM. The effects of additional treatments were 238 
evaluated statistically by including terms for the extra treatments in multivariate models. 239 
 240 
Results 241 
 242 
CM occurred in 1008 cases on the three study farms, of which 994, mainly mild to moderate 243 
cases, were enrolled (Table 2). Fourteen cases (1008-994) were excluded due to missing data. Ninety-244 
three cows were incorrectly allocated to treatment group, 124 received a NSAID concurrently and 106 245 
received additional systemic antibiotics. These data were included in the statistical analysis and included 246 
as covariates in the initial analysis. There was a large variety of pathogens obtained from the samples 247 
and they are listed in Table 3.  The most frequently isolated pathogens were E. coli (16.9%) and Strep. 248 
uberis (12%). These pathogens can be associated with typical environmental CM aetiology which was 249 
seen in both first and recurrent cases. Milk production, parity, underlying mastitis pathogens, CM 250 
history and treatment history did not differ significantly between groups. 251 
 252 
Quarter level 253 
 254 
Clinical persistence or recurrence at the quarter level is shown in Table 4.  EIMM and ECOMBO 255 
treatment reduced the clinical persistence or recurrence of CM by 8% and 6%, respectively (EIMM, 256 
OR= 0.38, 95% CI [0.12-0.50] and ECOMBO, OR=0.26, 95% CI [0.19-0.72]). ECOMBO did not 257 
further decrease clinical persistence or recurrence when compared to EIMM alone. The time to quarter 258 
level clinical persistence or recurrence for the three treatment groups is illustrated in Fig. 1. A posterior 259 
prediction of treatment effects is shown in Fig. 2, which is comparable to the survival curve in Fig. 1, 260 
demonstrating good model fit, illustrates the predicted outcome for the three treatment groups based on 261 
the final model.  Other significant covariates for quarter level clinical persistence or recurrence were 262 
farm, quarter location, parity and NSAID treatment. Infection severity was not a risk for persistence or 263 
recurrence (Table 6).  264 
 265 
Cow level 266 
 267 
Cow level clinical persistence or recurrence rates are presented in Table 5. The reduction in CM 268 
persistence or recurrence was 9% for EIMM and 8% after ECOMBO (EIMM, OR= 0.55, 95% CI [0.38-269 
0.77] and ECOMBO, OR=0.66, 95% CI [0.47-0.93]). The final multivariate model showed that, apart 270 
from treatment regime, the significant covariates for clinical persistence or recurrence of CM at the cow 271 
level were farm, quarter location, parity, and Strep. uberis infection compared to E. coli infection (Table 272 
7).  273 
 274 
Discussion 275 
 276 
Bacteriological cure is classically used to assess mastitis treatment efficacy because it is a 277 
concise and objective parameter. On farm, treatment efficacy is evaluated based on resolution of clinical 278 
signs and lack of recurrence. Persistence or recurrence of clinical signs often results in extended 279 
intramammary treatment or additional parenteral treatment, expecting a more efficient elimination of 280 
clinical signs and/or a lower probability of recurrence of clinical signs.  281 
 282 
In this study, EIMM and ECOMBO were associated with a significant decrease in the probability 283 
of persistent or recurrent CM, both at the quarter level and at the cow level when compared to SIMM, in 284 
line with other recent findings (Pinzón-Sánchez et al., 2011). This suggests that extended and more 285 
‘aggressive’ treatment regimens can be beneficial for individual cows when clinical persistence or 286 
recurrence rates are high. A reduction in persistent or recurrent CM can be due simply to higher 287 
bacteriological cure after extended treatment (Sol et al., 2000, Oliver et al., 2004, Pinzón-Sánchez et al. 288 
2011), though it could also be as a result of  a decrease in the risk of re-infection with another pathogen.   289 
 290 
Our study differs from earlier studies in that E. coli was the most frequently isolated pathogen 291 
(Table 3). Döpfer et al. (1999) and Bradley and Green (2001) used molecular methods to demonstrate 292 
that clinical E. coli mastitis can recur, and that recurrent E. coli strains may be cow adapted. We found 293 
that Strep. uberis CM was nearly twice as likely to clinically persist or recur as E. coli CM. We also 294 
found a numerical reduction in clinical persistence or recurrence of E. coli CM after EIMM compared to 295 
SIMM (data not shown), although the difference was not statistically significant. This is in contrast to 296 
studies that show that antibiotic treatment of E. coli CM should be avoided because it is not effective 297 
(Pyörälä et al., 1998) or not expected to be effective in recurrent cases (Schukken et al., 2004). 298 
 299 
An often overlooked, indirect effect of increasing bacteriological cure is a lower infection 300 
pressure, simply because cured quarters are no longer able to spread infection to other quarters or other 301 
cows (Swinkels et al., 2005a, 2005b; Barlow et al., 2009). This means extended treatment may not only 302 
result in a higher bacteriological cure but may also have an indirect effect in a herd, such as an overall 303 
lower re-infection rate and thus, less persistence or recurrence of CM. Because treatment strategies were 304 
compared within herds, the ‘infection pressure’ for each treatment group was the same and could not 305 
have influenced differences between treatment groups.  306 
 307 
Clinical persistence or recurrence of CM was higher at the level of the cow (58%) than the 308 
quarter (43%). This was expected, because at the cow level, CM can occur in any of the four quarters. 309 
The difference between clinical persistence or recurrence at the cow and quarter level was not large and 310 
indicates that the probability of CM recurrence in the other three quarters was relatively low and shows 311 
persistence or recurrence mainly occurred in the originally affected quarter. This can be either caused by 312 
the fact that chronically infected quarters may ‘flare-up’ after treatment (Houben et al., 1993, Lam et al., 313 
1996, Zadoks et al., 2001) and/or that previously infected quarters are more susceptible to new infection 314 
(Zadoks et al., 2001).  315 
 316 
Our model was not built to compare ECOMBO and EIMM treatment directly as both were 317 
compared to SIMM. However, we believe ECOMBO treatment was not likely to have reduced 318 
persistence or recurrence of CM, at the quarter or cow level, beyond EIMM treatment. In contrast, the 319 
probability of clinical persistence or recurrence at the cow level was numerically higher in the 320 
ECOMBO group than in the EIMM group (Figure 1). However, it is possible that additional parenteral 321 
treatment in the ECOMBO group contributed to removal of subclinical infections (with minor 322 
pathogens) in the same cow (Sérieys et al., 2005), making those quarters more susceptible to new 323 
infections, thereby increasing the likelihood of subsequent CM and recurrence at the cow level. This is 324 
in line with the findings of Wenz et al. (2005), who concluded that parenteral treatment with a 325 
cephalosporin in addition to standard IMM cephalosporin treatment had no effect on recurrence of mild 326 
E. coli CM. Our results suggest that ECOMBO treatment with cefquinome may have no added value 327 
over EIMM treatment on farms with a high rate of recurrence where environmental pathogens 328 
predominate.  329 
 330 
For quarters in cows with an additional NSAID treatment, clinical persistence or recurrence was 331 
significantly higher (Table 6) compared to quarters in cows where NSAID treatment was not used. This 332 
is unexpected, because clinical symptoms are assumed to resolve more quickly after NSAID treatment. 333 
It may be that farm personnel used additional NSAID treatment in cows which they suspected clinical 334 
symptoms to resolve more slowly or which they perceived to be more sensitive to mastitis and thus more 335 
likely to recur. 336 
 337 
Prudent antibiotic use is a pre-requisite in modern agriculture and demands evidence-based 338 
justification for extended treatment. Exposure of bacteria to antibiotics increases the risk of selection for 339 
antibiotic resistance. EIMM treatment led to increased antibiotic use (from three to six tubes per case) 340 
and an increase in the duration of exposure to antimicrobials, which was not compensated by the 8-9% 341 
decrease in antibiotics used for recurrent cases. Thus, EIMM treatment led to an overall increase in 342 
antibiotic exposure, albeit that that exposure was largely confined to the mammary microbiome. The 343 
ECOMBO approach clearly increased antibiotic exposure compared to EIMM, as well as resulting in 344 
exposure of the gut flora to antimicrobial activity, and did not seem to lower persistence or recurrence of 345 
CM beyond EIMM. This study challenges the perception that additional parenteral treatment will 346 
improve the outcome of all CM and re-enforces the need for such approaches to only be used for known 347 
pathogens.  Whilst research suggests the use of parenteral antibiotics in severe mastitis cases may be 348 
helpful (Wenz et al., 2001, Erskine et al., 2002), further research is needed to better define the need 349 
and/or criteria for the use of systemic antibiotics in the treatment of mild and moderate cases of CM.   350 
 351 
In conclusion, both EIMM and ECOMBO cefquinome treatment significantly reduced the  352 
persistence or recurrence of CM on farms with a high incidence of mild and moderate environmental 353 
mastitis. Because additional extended parenteral treatment beyond EIMM may not reduce clinical 354 
persistence or recurrence, the producer and practitioner need to carefully consider such regimes from the 355 
perspective of prudent antibiotic use. 356 
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Table 1. The characteristics of the three herds involved in the study 480 
 481 
Farm ID    C    H    S 482 
Number of dairy cows 560   239   308 483 
BMSCC (x 1,000)  248   201   158 484 
ICRM    85   116   76 485 
Predominant Housing           Cubicles      Cubicles /pasture         Cubicles 486 
Predominant Breed                HF   HF   HF 487 
Approx 305 Day Yield (L) 9159            9003               11,309 488 
Milking Frequency  2X   2X   3X 489 
 490 
BMSCC, bulk milk somatic cell count, 12 months rolling mean; IRCM, incidence rate of clinical 491 
mastitis (number of quarter cases per 100 cows per year). 492 
 493 
 494 
 495 
 496 
 497 
 498 
 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
 507 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
 518 
 519 
 520 
 521 
 522 
 523 
 524 
 525 
Table 2. Severity of clinical mastitis, indicated in numbers of cases and percentages in parenthesis  526 
 527 
Clinical signs  SIMM   EIMM   ECOMBO  Total 528 
Grade 1  175 (57) 192 (60) 222 (60) 589 (59) 529 
Grade 2  109 (36) 100 (31) 125 (34) 334 (34) 530 
Grade 3  21   (7) 26   (8) 24   (6) 71   (7) 531 
Total   305 (100) 318 (100) 371 (100) 994 (100) 532 
 533 
Grade 1, mild (only clots in the milk); Grade 2, moderate (milk aspect changes in colour and / or 534 
consistency and / or presence of clots, heat, pain and/or swelling of the udder); and Grade 3, severe 535 
(milk aspect changes in colour and / or consistency and / or presence of clots, fever, depression, 536 
anorexia, very swollen udder); SIMM, intramammary cefquinome treatment for 1.5 days; EIMM,  537 
extended intramammary cefquinome treatment for 5 days; ECOMBO, extended combined 538 
intramammary and parenteral cefquinome treatment for 5 days. 539 
 540 
 541 
         
         
         
542 
Table 3. Aetiology of clinical mastitis cases per treatment group 543 
 544 
       Treatment 545 
Diagnosis (n)    SIMM   EIMM   ECOMBO  Total  Total (%) 546 
E. coli     54  55  59  168  16.90 547 
S. uberis    31  41  47  119  11.97 548 
S. dysgalactiae   14  13  22  49  4.93 549 
S. aureus    11  17  14  42  4.23 550 
Bacillus spp.    9  14  14  37  3.72 551 
Yeast spp.    14  13  7  34  3.42 552 
Enterococcus spp.   10  8  6  24  2.41 553 
Klebsiella spp.   6  8  3  17  1.71 554 
Prototheca spp.    11  3  1  15  1.51 555 
A. pyogenes    2  1  10  13  1.31 556 
Enterobacter spp.   4  2  3  9  0.91 557 
Aerococcus    3  1  4  8  0.80 558 
Pseudomonas spp.   2  3  3  8  0.80 559 
Other major pathogens   8  12  8  28  2.81 560 
Any Enterobacterial involvement 76  83  77  236  23.74 561 
Mixed aetiology (major pathogens) 16  22  30  68  6.84 562 
Corynebacterium spp.   17  19  30  66  6.64 563 
Coagulase negative Staph   12  11  30  53  5.33 564 
Mixed aetiology (minor pathogens) 9  11  13  33  3.32 565 
Contaminated    11  11  8  30  3.02 566 
No growth    61  53  59  173  17.40 567 
Grand Total    305  318  371  994  100.00  568 
 569 
SIMM, intramammary cefquinome treatment for 1.5 days; EIMM, extended intramammary cefquinome 570 
treatment for 5 days; ECOMBO, extended combined intramammary and parenteral cefquinome 571 
treatment for 5 days. 572 
 573 
574 
Table 4. Numbers and percentages (between brackets) of persistence or recurrence of clinical mastitis at 575 
the quarter level within 105 days after the end of treatment of the initial clinical mastitis, irrespective of 576 
the isolated bacterial species 577 
 578 
      Treatment  579 
Recurrence   SIMM    EIMM   ECOMBO   Total 580 
No (%)   158 (52)  192 (60) 216 (58) 566 (57)  581 
Yes (%)   147 (48)  126 (40)* 155 (42)* 428 (43) 582 
Total    305   318  371  994 583 
 584 
SIMM, intramammary cefquinome treatment for 1.5 days; EIMM,  extended intramammary cefquinome 585 
treatment for 5 days; ECOMBO, extended combined intramammary and parenteral cefquinome 586 
treatment for 5 days; *, The odds ratio (OR) of recurrence after EIMM and after ECOMBO treatment 587 
were statistically significantly different from the SIMM treatment group (EIMM, OR = 0.38, 95% CI 588 
[0.12-0.50] and ECOMBO, OR=0.26, 95% CI [0.19-0.72]. 589 
590 
Table 5. Numbers and percentages (between brackets) of persistence or recurrence of clinical mastitis at 591 
the cow level within 105 days after the end of treatment of the initial clinical mastitis, irrespective of the 592 
isolated bacterial species 593 
 594 
      Treatment  595 
Recurrence   SIMM    EIMM   ECOMBO   Total 596 
No (%)   111 (36)  144 (45) 162 (44) 417 (42)  597 
Yes (%)   194 (64)  174 (55)* 209 (56)* 577 (58) 598 
Total    305   318  371  994 599 
 600 
SIMM, intramammary cefquinome treatment for 1.5 days; EIMM,  extended intramammary cefquinome 601 
treatment for 5 days; ECOMBO, extended combined intramammary and parenteral cefquinome 602 
treatment for 5 days; *, the Odds Ratio (OR) of recurrence of EIMM and ECOMBO treatment were 603 
statistically significantly different from the SIMM treatment group (EIMM, OR= 0.55, 95% CI [0.38-604 
0.77] and ECOMBO, OR=0.66, 95% CI [0.47-0.93].  605 
Table 6. Final model outcome of the multivariate analysis of probability of clinical persistence or 606 
recurrence at the quarter level 607 
 608 
Model term  OR     95% CI 609 
Intercept=-3.2   610 
Ref= SIMM  611 
EIMM              0.26  0.12 0.50 612 
ECOMBO  0.38  0.19 0.72 613 
Ref = farm C* 614 
Farm H  2.58  1.35 5.32 615 
Farm S  0.79  0.36 1.73 616 
Ref= quarter LF 617 
Quarter LH  0.66  0.35 1.24 618 
Quarter RF  0.49  0.25 0.93  619 
Quarter RH  1.08  0.56 2.09 620 
Ref=Parity 1 621 
Parity 2  1.31  0.52 3.27 622 
Parity 3  3.23  1.25 8.25 623 
Parity 4  4.74  1.73 13.17 624 
Parity 5+  3.29  1.32 8.26 625 
Ref= Grade 1f 626 
Grade 2  1.04  0.63 1.73 627 
Grade 3  1.62  0.51 5.23 628 
Ref= Yes NSAIDg 629 
No NSAID  0.30  0.11 0.74 630 
 631 
Ref, reference parameter; SIMM, intramammary cefquinome treatment for 1.5 days; EIMM,  extended 632 
intramammary cefquinome treatment for 5 days; ECOMBO, extended combined intramammary and 633 
parenteral cefquinome treatment for 5 days; *, for farm characteristics, see Table 1; LF, left front; RF, 634 
right front; LH, left hind; LF, left front; Grade 1, Mild; Only clots in the milk, Grade 2, Moderate; Heat, 635 
pain and/or swelling of the udder,  Grade 3, Severe; Fever, depression, anorexia, very swollen udder; yes 636 
NSAID, non-steroidal anti-inflammatory drug given in addition to antibiotics.  637 
638 
Table 7. Final outcome of the multivariate model of the probability of clinical persistence or recurrence 639 
at the cow level 640 
 641 
Model term  OR     95% CI 642 
Intercept= -4.0  643 
Ref= SIMM  644 
EIMM               0.55  0.38 0.77 645 
ECOMBO  0.66  0.47 0.93 646 
Ref = farm C* 647 
Farm H  1.74  1.22 2.48 648 
Farm S  0.90  0.59 1.34 649 
Ref=Parity 1 650 
Parity 2  1.80  1.10 3.03 651 
Parity 3  3.10  1.85 5.55 652 
Parity 4  3.31  1.93 6.10 653 
Parity 5+  3.32  2.04 5.71 654 
Ref= E. coli† 655 
S. uberis  1.96  1.21 3.20 656 
 657 
Ref, reference parameter; SIMM, intramammary cefquinome treatment for 1.5 days; EIMM,  extended 658 
intramammary cefquinome treatment for 5 days; ECOMBO, extended combined intramammary and 659 
parenteral cefquinome treatment for 5 days; *, for farm characteristics, see Table 1; †, recurrence of 660 
clinical mastitis causing pathogen - recurrence of other bacteria was not significantly different from the 661 
reference pathogen, E. coli. 662 
Figure 1. Legend 663 
 664 
 665 
Figure 1 Kaplan Meier survival curve, illustrating cumulative survival (=no persistence or recurrence) at 666 
the quarter level, during 105 days after initial treatment for the 3 different treatment groups 667 
 668 
 669 
 670 
 671 
 672 
x, short intramammary cefquinome treatment (SIMM) for 1.5 days; +,  extended intramammary 673 
(EIMM) cefquinome treatment for 5 days;  ◊, extended combined intramammary and parenteral 674 
cefquinome treatment (ECOMBO) for 5 days. 675 
 676 
Both EIMM and ECOMBO treatment reduced persistence or recurrence of clinical mastitis significantly 677 
compared to the SIMM (EIMM, OR = 0.38, 95% CI [0.12-0.50] and ECOMBO, OR=0.26, 95% CI 678 
[0.19-0.72]. 679 
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Figure 2.   701 
 702 
The Bayesian prediction of survival (=no persistence or recurrence) of clinical mastitis after initial 703 
treatment from the multilevel model. The prediction is made for every quarter assuming it could receive 704 
each treatment 705 
 706 
 707 
x, short intramammary cefquinome treatment (SIMM) for 1.5 days; +,  extended intramammary 708 
(EIMM) cefquinome treatment for 5 days;  ◊, extended combined intramammary and parenteral 709 
cefquinome treatment (ECOMBO) for 5 days. 710 
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